Pharma big $$$ drugs being pushed out. But, don’t you dare order any of those cheap COVID drugs.<\/p>\n
Would you partake in any of this when ivermectin, fluvoxamine, NAC, Vitamin D and a host of other non-toxic drugs could help you? It’s all corrupt to the core. <\/p>\n
Internal email:<\/p>\n
Dear EUA Points of Contact, Pharmacy Chiefs, and VISN Pharmacy Executives<\/p>\n
Please see below updates on novel mAb and oral agents. <\/p>\n
Novel Agents
\n\u2022\tThree new agents (included two oral antivirals) have recently been granted EUA by the FDA
\n\u2022\tPlease review criteria for these agents carefully. Sites that believe they may have a patient in the next 2-3 weeks may now choose to opt-in here: COVID-19 Emergency Use Authorization (sharepoint.com)
\n\u2022\tThese drugs will be made available on a first-come first-serve basis starting mid-January. More information will be forthcoming as it becomes available.
\n\u2022\tNote: supply of these agents is extremely limited so please ensure that staff are familiar with limitations\/criteria for each agent before opting-in
\n\u2022\tBelow is preliminary information about the three agents \u2013 please refer to the EUA fact sheet for most accurate\/detailed information. <\/p>\n
Evusheld is the new product from AstraZeneca and contains tixagevimab (TIX) packaged with cilgavimab (CIL).
\n\u2022\tUse of this product is limited to those who are not currently infected with SARS-CoV-2 and who have not had a known recent exposure to an individual infected with SARS-CoV-2 AND
\no\tWho have moderate to severe immune compromise due to a medical condition or receipt of immunosuppressive medications or treatments and may not mount an adequate immune response to COVID-19 vaccination OR
\no\tFor whom vaccination with any available COVID-19 vaccine, according to the approved or authorized schedule, is not recommended due to a history of severe adverse reaction (e.g., severe allergic reaction) to a COVID-19 vaccine(s) and\/or COVID-19 vaccine component(s).
\n\u2022\tNote: Refusal of vaccine does NOT constitute eligibility if above criteria are not met.
\n\u2022\tEvusheld is NOT authorized for treatment, or post-exposure prophylaxis and must be used in strict congruence with EUA documentation.
\n\u2022\tEvusheld is not a substitute for vaccination in individuals for whom COVID-19 vaccination is recommended.
\n\u2022\tEvusheld Provider fact sheet<\/p>\n
Paxlovid is the new oral product from Pfizer and contains Nirmatrelvir packaged with Ritonavir (RTV)
\n\u2022\tPaxlovid is authorized
\no\tFor patients with high risk for progression to severe disease (as defined by CDC)
\no\tFor patients with laboratory confirmed mild to moderate COVID-19 provided the patient is within 5 days of symptom onset
\n\u2022\tPaxlovid is not authorized
\no\tFor initiation of treatment in patients requiring hospitalization due to severe or critical COVID-19
\no\tFor pre-exposure or post-exposure prophylaxis for prevention of COVID-19
\no\tFor use longer than 5 consecutive days
\no\tFor patients with severe renal impairment (eGFR < 30 mL\/min) or severe hepatic impairment (Child-Pugh Class C) \u2013 dose adjustment available for moderate renal impairment
\n\u2022\tPaxlovid has multiple contraindications (strong CYP3A inducers or drugs highly dependent on CYP3A for clearance and for which elevated concentrations are associated with serious and\/or life-threatening reactions). See EUA documentation for full list of drugs
\n\u2022\tDosing
\no\tStandard: 2 tablets (300 mg) of Nirmatrelvir and 1 tablet (100 mg) of RTV every 12 hours for 5 consecutive days
\no\tRenal: 1 tablet (150 mg) of Nirmatrelvir and 1 tablet (100 mg) of RTV every 12 hours for 5 consecutive days
\n\u2022\tPaxlovid Provider fact sheet<\/p>\n
Molnupiravir is the new oral product from Merck
\n\u2022\tMolnupiravir is authorized
\no\tFor patients with high risk for progression to severe disease (as defined by CDC)
\no\tFor patients with laboratory confirmed mild to moderate COVID-19 provided the patient is within 5 days of symptom onset
\n\u2022\tMolnupiravir is not authorized
\no\tFor use in patients less than 18 years of age
\no\tFor initiation of treatment in patients requiring hospitalization due to COVID-19
\no\tFor use longer than 5 consecutive days
\no\tFor pre-exposure or post-exposure prophylaxis for prevention of COVID-19
\no\tFor patients with severe renal impairment (eGFR < 30 mL\/min) or severe hepatic impairment (Child-Pugh Class C) \u2013 dose adjustment available for moderate renal impairment
\n\u2022\tMolnupiravir has specific guidance and considerations for use in patients who are or may be pregnant.
\n\u2022\tStandard Dosing: 4 capsules (800 mg) of Molnupiravir every 12 hours for 5 consecutive days
\n\u2022\tMolnupiravir Provider fact sheet<\/p>\n
Thank you<\/p>\n","protected":false},"excerpt":{"rendered":"
Pharma big $$$ drugs being pushed out. But, don’t you dare order any of those cheap COVID drugs. Would you partake in any of this when ivermectin, fluvoxamine, NAC, Vitamin D and a host of other non-toxic drugs could help … Continue reading